{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Control+Subjects", "query": { "condition": "Normal Control Subjects" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 807, "total_pages": 81, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Control+Subjects&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T06:15:51.202Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02669862", "title": "A Study of A-101 Solution in Subjects With Common Warts.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Common Warts" ], "interventions": [ { "name": "A-101 Solution 40", "type": "DRUG" }, { "name": "A-101 Solution 45", "type": "DRUG" }, { "name": "Vehicle Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aclaris Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2015-12-21", "completion_date": "2016-09-16", "has_results": true, "last_update_posted_date": "2018-12-07", "last_synced_at": "2026-05-22T06:15:51.202Z", "location_count": 1, "location_summary": "Wayne, Pennsylvania", "locations": [ { "city": "Wayne", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02669862" }, { "nct_id": "NCT01494467", "title": "Phase 3 Papulopustular Rosacea Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Papulopustular Rosacea" ], "interventions": [ { "name": "CD5024", "type": "DRUG" }, { "name": "Azelaic acid 15% Gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 688, "start_date": "2011-12", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2021-02-18", "last_synced_at": "2026-05-22T06:15:51.202Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Oceanside", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01494467" }, { "nct_id": "NCT00137969", "title": "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 262, "start_date": "2005-05-10", "completion_date": "2008-08-25", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-05-22T06:15:51.202Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00137969" }, { "nct_id": "NCT03285477", "title": "A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Actinic Keratoses" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "KX2-391 Ointment 1%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Almirall, S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 351, "start_date": "2017-09-18", "completion_date": "2019-04-24", "has_results": true, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-05-22T06:15:51.202Z", "location_count": 30, "location_summary": "Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Fremont", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03285477" }, { "nct_id": "NCT01276639", "title": "A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "CP-690,550", "type": "DRUG" }, { "name": "Placebo/CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 901, "start_date": "2011-03", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-09-19", "last_synced_at": "2026-05-22T06:15:51.202Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Irvine, California • San Diego, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01276639" }, { "nct_id": "NCT01138735", "title": "Epiduo Pediatric Acne Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acne" ], "interventions": [ { "name": "adapalene/benzoyl peroxide", "type": "DRUG" }, { "name": "Topical Gel Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "9 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "9 Years to 11 Years" }, "enrollment_count": 285, "start_date": "2010-06", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2021-02-18", "last_synced_at": "2026-05-22T06:15:51.202Z", "location_count": 20, "location_summary": "Birmingham, Alabama • San Diego, California • Santa Rosa, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Miramar", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01138735" }, { "nct_id": "NCT00624338", "title": "Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Atacicept 75 mg", "type": "DRUG" }, { "name": "Atacicept 150 mg", "type": "DRUG" }, { "name": "Placebo Comparator", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 461, "start_date": "2008-01", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2016-03-14", "last_synced_at": "2026-05-22T06:15:51.202Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00624338" }, { "nct_id": "NCT01273389", "title": "An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "CNTO 136", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 25, "start_date": "2011-08", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2016-03-24", "last_synced_at": "2026-05-22T06:15:51.202Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Success", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01273389" }, { "nct_id": "NCT04888585", "title": "Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "ABBV-154", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 473, "start_date": "2021-06-23", "completion_date": "2023-08-04", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-05-22T06:15:51.202Z", "location_count": 101, "location_summary": "Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04888585" }, { "nct_id": "NCT02885181", "title": "Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "GS-9876", "type": "DRUG" }, { "name": "Filgotinib", "type": "DRUG" }, { "name": "GS-9876 placebo", "type": "DRUG" }, { "name": "Filgotinib placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 83, "start_date": "2016-09-21", "completion_date": "2017-09-20", "has_results": true, "last_update_posted_date": "2018-09-19", "last_synced_at": "2026-05-22T06:15:51.202Z", "location_count": 9, "location_summary": "DeBary, Florida • Sarasota, Florida • Canton, Georgia + 6 more", "locations": [ { "city": "DeBary", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Canton", "state": "Georgia" }, { "city": "Elizabethtown", "state": "Kentucky" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02885181" } ] }